Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02635698
Other study ID # 14.21.CLI
Secondary ID
Status Completed
Phase N/A
First received December 11, 2015
Last updated November 9, 2017
Start date November 2015
Est. completion date October 2017

Study information

Verified date November 2017
Source Nestlé
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Compare percent change in loss of body weight between the OPTIFAST program and a food-based energy-deficit program


Recruitment information / eligibility

Status Completed
Enrollment 330
Est. completion date October 2017
Est. primary completion date October 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- Adult males and females between 18 and 70 years

- Obese (BMI > 30 kg/m2 and 55 kg/m2)

- Non-smokers or smoking cessation > 6 months

- < 14 alcoholic beverages per week

- Willing and able to give informed consent

Exclusion Criteria:

- Active participation in any weight loss program within previous 3 months

- Weight changes of > 5% body weight within previous 3 months

- Participated in an Optifast program within prior 5 years

- Prior bariatric surgery or liposuction

- Use of any medication prescribed for weight loss in the past 3 months

- Current major disease or GI disease that is poorly controlled (Crohn's, ulcerative colitis)

- Type 1 DM

- Current ESRD

- Current COPD

- Any major or active hepatic disease requiring inpatient or outpatient treatment

- History of acute pancreatitis in the past year

- Active cancer treatment in the past 2 years other than non-malignant skin cancers

- Uncontrolled hypertension (Blood pressure 160/100 or greater)

- Hemoglobin A1c > 10%

- Recent CV event in past 6 months

- Pregnancy, childbirth, or nursing within prior 6 months

- Eating Attitudes Test (EAT-26) > 30

- Current major depressive disorder with Center for Epidemiological Studies Depression Scale-Revised (CESD-R) score > 16

- Schizophrenia, history of bipolar disorder

- Recent hospitalization for psychiatric illness in past 6 months

- Dependence on alcohol or sedative-hypnotic drugs

- Intolerance or allergy to Optifast product

- Unable to read/speak English

- Orthopedic limitation preventing participation in regular physical activity

- Untreated thyroid disease, abnormal TSH, non on stable dose of hormone replacement for hyperthyroidism

- Major surgery defined as any surgical procedure that might require prolonged convalescence or limit participation in the program in any way

- Inability to complete the 7-day run-in satisfactorily

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Optifast
medically-supervised weight management program
Food-Based
low-energy, low-fat diet

Locations

Country Name City State
United States Alaska Premier Health Anchorage Alaska
United States University of Michigan Health System Ann Arbor Michigan
United States Neuro-Behavioral Clinical Research, Inc. Canton Ohio
United States Central Ohio Nutrition Center, Inc. Gahanna Ohio
United States Brody School of Medicine, East Carolina University Greenville North Carolina
United States Thomas Jefferson University Philadelphia Pennsylvania
United States Alexian Brothers Weight Loss Solutions Schaumburg Illinois
United States Houston Center for Clinical Research Sugar Land Texas
United States Wake Forest School of Medicine Winston-Salem North Carolina

Sponsors (2)

Lead Sponsor Collaborator
Nestlé TKL Research, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percent weight change Percent change in body weight between Initial Visit/Baseline and 26 weeks 26 weeks
Primary Percent weight change Percent change in body weight between Initial Visit/Baseline and 52 weeks 52 weeks
Secondary Ability to meet weight goals Percentage of subjects meeting short- and long-term weight loss goals 52 weeks
Secondary Change in anthropometrics change in BMI in kg/m^2 from baseline to 52 weeks 52 weeks
Secondary Change in cardiometabolic outcomes Change in 10-year cardiovascular risk score (% likelihood to develop CVD in 10 years) 52 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2